Vor Biopharma (VOR) Gains from Investment Securities (2025 - 2026)
Vor Biopharma's (VOR) quarterly Gains from Investment Securities came in at $188.4 million in Q1 2026, up 110.73% on a QoQ basis from -$1.8 billion in Q4 2025.
Vor Biopharma (VOR) Gains from Investment Securities (2025 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 2 years of Gains from Investment Securities data on file, last reported at $188.4 million in Q1 2026.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $188.4 million in Q1 2026; TTM through Mar 2026 was $522.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $334.4 million, changed N/A from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $188.4 million, up from -$1.8 billion in the prior quarter.
- Over the last five years, Gains from Investment Securities for VOR reached as high as $1.3 billion in Q2 2025 and fell as low as -$1.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Vor Biopharma | 853.35 Mn | 853.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188.36 Mn |
| Mar 31, 2026 | 188.36 Mn |
| Dec 31, 2025 | -1.76 Bn |
| Dec 31, 2025 | -1.76 Bn |
| Sep 30, 2025 | 790.46 Mn |
| Sep 30, 2025 | 790.46 Mn |
| Jun 30, 2025 | 1.30 Bn |
| Jun 30, 2025 | 1.30 Bn |